Kidney Cancer

Latest News

ALLO-316 shows encouraging CAR activity in advanced ccRCC
ALLO-316 shows encouraging CAR activity in advanced ccRCC

November 8th 2024

Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.

Casdatifan demonstrates encouraging clinical activity in renal cell carcinoma
Casdatifan demonstrates encouraging clinical activity in renal cell carcinoma

November 4th 2024

FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC
FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC

October 29th 2024

Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC
Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC

September 25th 2024

Benmelstobart plus anlotinib improves PFS, ORR vs sunitinib in aRCC
Benmelstobart plus anlotinib improves PFS, ORR vs sunitinib in aRCC

September 19th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.